Safety of antiandrogen therapy for treating prostate cancer

@article{Ricci2014SafetyOA,
  title={Safety of antiandrogen therapy for treating prostate cancer},
  author={Francesco Ricci and Giulia Buzzatti and Alessandra Rubagotti and Francesco Boccardo},
  journal={Expert Opinion on Drug Safety},
  year={2014},
  volume={13},
  pages={1483 - 1499}
}
Introduction: Antiandrogens are a treatment option in patients with prostate cancer, given either in combination with androgen deprivation or, in selected cases, as monotherapy. New-generation antiandrogens have been recently introduced in clinical practice (enzalutamide) or are under evaluation in clinical trials (ARN-509). Areas covered: This review elucidates the safety profile of antiandrogens, in particular focusing on the tolerability profile of each drug either when employed in… 

Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse

The authors characterized the mechanism of the immunosuppression and found that medical ADT interfered with initial T cell priming rather than reactivation and expansion, suggesting that careful regulation of timing and dose could improve the efficacy of this combination therapy.

Cardiovascular toxicities of systemic treatments of prostate cancer

Clinical trial methodology could be improved by the enrolment of greater numbers of patients >65 years of age, and the use of comprehensive cardiological evaluations, and closer collaboration between oncologists and cardiologists is essential for the identification and/or management of cardiovascular adverse events in patients with prostate cancer.

Is Irisin an Anticarcinogenic Peptide

Investigation whether there is a role of irisin on human prostate cancer cell viability and whether the effects of peptides on cancer thay may reduce obesity have been investigated.

Influence of androgen deprivation therapy on serum urate levels in patients with prostate cancer: A retrospective observational study

Results showed that longitudinal serum urate levels were significantly reduced in men receiving androgen deprivation therapy (ADT), suggesting that androgen could have an independent role in urate homeostasis.

Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide

These results confirm the therapeutic effectiveness of squalenoyl siRNA nanomedicine for PCa based on siRNA TMPRSS2-ERG and compare or combine the developed siRNA to flutamide (FLU), one of the gold-standard treatment of PCa.

Risk of Fracture During Androgen Deprivation Therapy Among Patients With Prostate Cancer: A Systematic Review and Meta-Analysis of Cohort Studies

Cumulative evidence supports the association of elevated fracture risk with ADT among patients with prostate cancer, including those with different disease conditions, treatment regimens, dose levels, and fracture sites.

Baicalein suppresses the androgen receptor (AR)-mediated prostate cancer progression via inhibiting the AR N-C dimerization and AR-coactivators interaction

Baicalein may be developed as an effective anti-AR therapy via its ability to inhibit AR transactivation and AR-mediated PCa cell growth.

Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer Who Underwent Orchiectomy: A Systematic Review and Meta-analysis

Evidence suggests that patients with mPCa who underwent orchiectomy receiving Nilutamide showed significant improvement in progression-free survival and overall survival response rate and clinical benefits in comparison with the placebo group.

Nuclear receptors: recent drug discovery for cancer therapies.

This article overviews NR-based drug discovery in cancer and related resistance mechanisms, focusing on novel strategies for targeting well-established NR targets, including ERα, AR, the glucocorticoid receptor and the progesterone receptor, as well as opportunities to target other NRs that are attracting interest in immuno-oncology.

References

SHOWING 1-10 OF 110 REFERENCES

Antiandrogens in the treatment of prostate cancer.

Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?

Patients with a higher disease burden (PSA >400 ng/ml) may decide that quality of life and symptomatic benefits outweigh the slight survival disadvantage seen in clinical trials and opt for bicalutamide monotherapy as an alternative to castration.

Antiandrogen treatments in locally advanced prostate cancer: are they all the same?

  • D. Gillatt
  • Medicine, Biology
    Journal of Cancer Research and Clinical Oncology
  • 2006
The available evidence indicates that the different antiandrogens should not be regarded as equivalents in clinical practice and so the choice of treatment for patients with prostate cancer should be made on an individual basis.

Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer

It is established that DES is equivalent to orchiectomy as a comparator for treatments of advanced prostate cancer and the findings on four questions are summarized.

Antiandrogen monotherapy in the management of advanced prostate cancer.

Preliminary results suggest that bicalutamide (Casodex, Zeneca Ltd) is as effective as castration in non-metastatic disease.

Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer

A review of 2 AR-targeted agents recently approved by the Food and Drug Administration and 2 direct antagonists, enzalutamide and ARN-509, that induce apoptosis without agonist activity in preclinical models shows great promise for patients with advanced disease.

Secondary hormonal therapy for advanced prostate cancer.

ARN-509: a novel antiandrogen for prostate cancer treatment.

ARS-509 exhibits characteristics predicting a higher therapeutic index with a greater potential to reach maximally efficacious doses in man than current AR antagonists, and offers preclinical proof of principle for ARN-509 as a promising therapeutic in bothCastration-sensitive and castration-resistant forms of prostate cancer.

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

  • D. RathkopfM. Morris H. Scher
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
ARN-509 was safe and well tolerated, displayed dose-proportional pharmacokinetics, and demonstrated pharmacodynamic and antitumor activity across all dose levels tested.
...